IFNG and neoplasm: Although PD-L1 expression, tumor mutational burden (TMB), and interferon gamma (INFγ) are believed to be markers of response rates, these characteristics have not consistently applied to all tumor types, show a range of temporal and spatial variability, and are changeable with different types of therapy [38].